Market Research Report
Global Automated Insulin Delivery Systems Market - 2021-2028
|Global Automated Insulin Delivery Systems Market - 2021-2028|
Published: February 16, 2022
Content info: 185 Pages
Delivery time: 2 business days
The global automated insulin delivery systems market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Automated insulin delivery systems are automated (or semi-automated) systems that enable patients with diabetes, mainly type 1, to control their blood glucose levels by automatically adjusting insulin delivery.
Advancement in next-generation automatic insulin delivery systems is expected to drive market growth.
RocketAP, a brand-new automated insulin delivery (AID) algorithm, helped adolescents with type 1 diabetes stay more time in range after meals, even when they didn't take mealtime (bolus) insulin, according to tiny but interesting research. RocketAP is similar to Control-IQ, but it has a unique system feature that can detect unscheduled meals and provide bolus insulin fast to minimize high blood sugar levels afterward (hyperglycemia). Moreover, a study was conducted where Tandem insulin pumps and Dexcom G6 CGMs were used, and the results were impressive and could indicate the first steps toward a fully closed-loop algorithm. Thus, from the above statements, the market is expected to boost in the forecast period.
The drawbacks associated with automated insulin delivery systems are expected to hamper market growth.
Infusion sets that are kinked or unintentionally torn out, malfunctioning pumps, dead batteries, and infusion site adhesion concerns are major insulin pump issues. There are also budget pressures when it comes to reimbursement. Pumps, CGM sensors, and AID systems are all expensive, and most people can only afford to use them if they have insurance. Even DIY systems need customers to pay a yearly charge for a software development license and the upfront price of any hardware needed to link their pump and algorithm. There is a risk of skin infection or allergic reaction by infusion pumps. Thus, the market is expected to get hampered in the forecast period from the above statements.
The epidemic caused by the SARS-CoV-2 virus resulted in a global lockdown and wreaked havoc on the automated insulin delivery systems market. In hospitalized patients with COVID-19, type 1 and type 2 diabetes are associated with an increased risk of death, with a larger number of deaths in people with type 1 and type 2 diabetes living in the most deprived neighborhoods than those living in the least deprived districts. Moreover, hyperglycemia and obesity are linked to COVID-19 mortality in persons with diabetes. Secondly, SARS-CoV-2 can, directly and indirectly, impact glucose metabolism by triggering beta cell death and raising insulin resistance. Self-management of type 1 diabetes (T1D) can be difficult, requiring numerous daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), all of which are guided by glucose self-monitoring.
Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Reusable Insulin Pens segment is expected to hold the largest market share in automated insulin delivery systems market
The reusable insulin pens segment is expected to dominate in 2020. The most significant advantages are durability, which helps overcome the barrier of huge storage space necessary for disposable insulin pens, and the ability to carry a 3-5-day supply. Meanwhile, reusable insulin pens are more accurate in meeting dose accuracy according to international standards (ISO-11608-1). They are equipped with additional features such as audible, visual, and tactile feedback during dose dialing to aid application and reduce the risk of human errors during handling. In addition, the newer reusable insulin pens have the advantage of adjusting a selected dose without losing insulin, as opposed to previous pens with one-directional dial constraints that made it impossible to dial "back" the dose.
Additionally, the process of resetting the pen after changing to a new cartridge in older reusable pens was quite tough, as the piston rod had to be re-wound to its starting point. On the other hand, the newest reusable pens allow the user to insert the piston rod back into the pen rather than turning it. Reusable pens may be less expensive than vials and syringes, in addition to the benefits listed above. Furthermore, these insulin delivery pens are environmentally benign and may have an advantage over disposable pens in contributing to less plastic waste. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
North America region holds the largest market share in the global automated insulin delivery systems market
In 2020, North America accounted for the highest revenue share. The increasing prevalence of the diabetic population, technological advancement in the devices, well-established healthcare facilities in the region, acquisition and collaboration by the market players are some of the factors due to which the market is expected to boost in the forecast period. For instance, According to the Centers for Disease Control (CDC), diabetes was the seventh leading cause of death in the United States. In 2018, an estimated 1.5 million new cases of diabetes were diagnosed among U.S. adults aged 18 years or older. In contrast, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes, and nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents.
Moreover, Abbott and Tandem Diabetes Care signed an agreement in June 2020 to create and market Abbott's continuous glucose monitoring (CGM) systems alongside Tandem's revolutionary insulin delivery systems to provide diabetes care solutions that address the gap in the market. Insulet also teamed with the other two businesses in February 2020 to advance diabetes management technology. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Major key players in the automated insulin delivery systems market are Medtronic, Novo Nordisk, Insulet Corporation , Tandem Diabetes Care, Inc, Ypsomed AG, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Biocon, Bigfoot Biomedical, Inc. and sanofi-aventis U.S. LLC.
Medtronic plc is an American-Irish registered medical device company primarily operating in the United States. It has an operational and executive headquarters in Fridley, Minnesota, in the US. Moreover, it develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders and diabetes. It is operated in 140 countries and employs over 104,950 people.
MiniMed 670G system: The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user-selectable rates) and administration of insulin boluses (in user-selectable amounts) to manage type 1 diabetes mellitus in persons seven years of age and older.
Visualize the composition of the automated insulin delivery systems market segmentation by device type, insulin pumps, pen needles, end user and region highlighting the key commercial assets and players.
Identify commercial opportunities in automated insulin delivery systems market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of automated insulin delivery systems market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global automated insulin delivery systems market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Global Automated Insulin Delivery Systems Market - By Device Type
Reusable Insulin Pens
Disposable Insulin Pens
Global Automated Insulin Delivery Systems Market - By Insulin Pumps
External/ Tethered Pumps
Implanted Insulin pump (IIP)
Closed loop insulin pump
Global Automated Insulin Delivery Systems Market - By Pen Needles
Standard Pen Needles
Safety Pen Needles
Global Automated Insulin Delivery Systems Market - By End user
Global Automated Insulin Delivery Systems Market - By Region
Middle East & Africa
LIST NOT EXHAUSTIVE